Optimised Fc variants with enhanced effector function

Abstract

In the present invention, IgG1 Fc variants were engineered and examined for affinity to the Fc receptor and for antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and antibody-dependent cell-mediated phagocytosis effector functions. In vivo function was also examined. Several variants exhibited enhanced effector function, and optimal Fc variants were selected. These variants can be used for engineering of therapeutic antibodies with the goal of achieving improved and optimal biological activities related to Fc effector functions.

Keywords::

• antibody-dependent cell-mediated cytotoxicity
• effector function
• engineered protein
• FcγR

Patent details

• Title Monochromatic Fluorescent Probe

• Assignee Japan Science & Tech Agency

• Inventors Umezawa Y, Sato M, Kawai Y.

• Priority date 26/08/03

• Filing date 25/08/04

• Publication date 03/03/05

• Publication no. WO2005019447